Real World Evidence Solutions Market: By Component (Claims Data, Clinical Data Setting, Pharmacy data, and Others), Indication (Cardiovascular Diseases, Oncology, Neurology, Urology, and Others), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Real World Evidence Solutions Market size was valued at USD 2.2 billion in 2022 and it is expected to grow to USD 8.6 billion growing at an 8.5% CAGR from 2023 to 2029. Real-world evidence is clinically gathered data through various studies and analyses which helps pharmaceuticals, medical device companies, and healthcare providers to implement new products or services in the market. Real-world data include randomized trials, simple trials, and observational studies. The growing amount of big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare are expected to positively impact the RWE solutions market. Pharmaceutical healthcare providers are ready to invest in the development of novel drugs and services, to the demand for drug discovery and development they are shifting to outsourcing data and services, to get data for early and late-stage phases. With the prevalence of increase in research & development expenditure, pharmaceuticals need preclinical and post-clinical services which drive the market for real-world evidence solutions. Although, key players started using real-world evidence solutions for randomized solutions clinical data results increase the opportunity real word evidence solutions. The lack of consensus and real-world evidence standard lacks in quality to be part of the body of evidence to determine the comparative effectiveness of different treatment options.  

Real World Evidence Solutions Market key Developments:
  • In August 2022, Trinity Lifesciences announced a partnership with Bain & Company. The partnership is to intend to pair extensive experience in the life sciences with the evidence-based solutions of Trinity Life Sciences.

Real World Evidence Solutions Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.50%

Largest Market

Asia Pacific

Fastest Growing Market

North America
Real World Evidence Solutions Market Dynamics

The increasing prevalence of clinical data outsourcing across the world is the major market driver in the Real-World Evidence Solutions Market during the forecast period. Outsourcing of data to gain new segment of the market through clinical trials provide information for the new research and development sector which drives the market, gaining information on a clinical trial, and other drug data to use for new research and development. Hence, this will drive global market growth at a significant rate.

Real World Evidence Solutions Market Segmentation

By Component
  • Claims Data
  • Clinical Data Setting
  • Pharmacy data
  • Others
By Indication
  • Cardiovascular diseases
  • Oncology
  • Neurology
  • Urology
  • Others
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA
LOCATION

Geography

Frequently Asked Questions

The real-world evidence solutions market size is USD 2.2 billion in 2022

The leading players in the Real-World Evidence Solutions Market are IQVIA, IBM, PPD Inc., Parexel International Corporation, PerkinElmer Inc., Icon Plc, Oracle, Syneos Health, Cegedim Health Data, Medpace,

Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation and Seven years forecast is presented from 2023 – 2029.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Real World Evidence Solutions Market Introduction 
2.1.Global Real World Evidence Solutions Market  - Taxonomy
2.2.Global Real World Evidence Solutions Market  - Definitions
2.2.1.Component
2.2.2.Indication
2.2.3.Geography
2.2.4.Region
3.Global Real World Evidence Solutions Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Real World Evidence Solutions Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Real World Evidence Solutions Market  By Component, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Claims Data
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Clinical Data Setting
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Pharmacy data
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Real World Evidence Solutions Market  By Indication, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Cardiovascular diseases
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Oncology
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Neurology
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Urology
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Real World Evidence Solutions Market  By Geography, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. The Asia Pacific
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Latin America
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. MEA
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.Global Real World Evidence Solutions Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Real World Evidence Solutions Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Component Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Claims Data
9.1.2.Clinical Data Setting
9.1.3.Pharmacy data
9.1.4.Others
9.2.  Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Cardiovascular diseases
9.2.2.Oncology
9.2.3.Neurology
9.2.4.Urology
9.2.5.Others
9.3.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.North America
9.3.2.Europe
9.3.3.The Asia Pacific
9.3.4.Latin America
9.3.5.MEA
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Real World Evidence Solutions Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Component Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Claims Data
10.1.2.Clinical Data Setting
10.1.3.Pharmacy data
10.1.4.Others
10.2.  Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Cardiovascular diseases
10.2.2.Oncology
10.2.3.Neurology
10.2.4.Urology
10.2.5.Others
10.3.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.North America
10.3.2.Europe
10.3.3.The Asia Pacific
10.3.4.Latin America
10.3.5.MEA
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Real World Evidence Solutions Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Component Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Claims Data
11.1.2.Clinical Data Setting
11.1.3.Pharmacy data
11.1.4.Others
11.2.  Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Cardiovascular diseases
11.2.2.Oncology
11.2.3.Neurology
11.2.4.Urology
11.2.5.Others
11.3.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.North America
11.3.2.Europe
11.3.3.The Asia Pacific
11.3.4.Latin America
11.3.5.MEA
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Real World Evidence Solutions Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Component Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Claims Data
12.1.2.Clinical Data Setting
12.1.3.Pharmacy data
12.1.4.Others
12.2.  Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Cardiovascular diseases
12.2.2.Oncology
12.2.3.Neurology
12.2.4.Urology
12.2.5.Others
12.3.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.North America
12.3.2.Europe
12.3.3.The Asia Pacific
12.3.4.Latin America
12.3.5.MEA
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Real World Evidence Solutions Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Component Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Claims Data
13.1.2.Clinical Data Setting
13.1.3.Pharmacy data
13.1.4.Others
13.2.  Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Cardiovascular diseases
13.2.2.Oncology
13.2.3.Neurology
13.2.4.Urology
13.2.5.Others
13.3.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.North America
13.3.2.Europe
13.3.3.The Asia Pacific
13.3.4.Latin America
13.3.5.MEA
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.IBM
14.2.2.PPD Inc
14.2.3.IQVIA
14.2.4.Medpace
14.2.5.PerkinElmer Inc.
14.2.6.Icon Plc,
14.2.7.Oracle
14.2.8.Parexel International Corporation
14.2.9.Syneos Health
14.2.10.Cegedim Health Data
15. Research Methodology 
16. Appendix and Abbreviations 
  • IBM
  • PPD Inc
  • IQVIA
  • Medpace
  • PerkinElmer Inc.
  • Icon Plc,
  • Oracle
  • Parexel International Corporation
  • Syneos Health
  • Cegedim Health Data

Adjacent Markets